Verbatim response from Perplexity
No telehealth services are confirmed to still safely offer compounded GLP-1s after the FDA’s March and June 2026 crackdowns; major platforms have either stopped offering them entirely or transitioned exclusively to FDA-approved alternatives like Wegovy, Zepbound, and Saxenda [3].
The FDA has issued over 100 warning letters across three enforcement waves (February, March, and June 2026) to telehealth firms for promoting compounded GLP-1s with false or misleading claims, explicitly stating these products lack proven safety, efficacy, or consistent quality [1][2][5]. High-profile companies that previously offered compounded versions have exited the model:
| Company | Status After Crackdown |
|---|---|
| Hims & Hers | Exited compounded semaglutide entirely in March 2026; now an authorized distributor of branded Wegovy and Ozempic [3][10] |
| Ro | Stopped compounded GLP-1s; now offers Wegovy and Zepbound [3] |
| Good Life | Eliminated compounded offerings; focuses on FDA-approved alternatives [3] |
| Medica Weight Loss, Ready Med, Clover Meds | Received June 2026 warning letters; compliance status unclear but likely halted or under review [1] |
| Beluga Health, OpenLoop, MD Integrations | Affiliations warned; at least 30% of warned companies linked to these groups, suggesting widespread cessation [6] |
The post-crackdown landscape is shifting to a manufacturer-centric distribution network, where Novo Nordisk and Eli Lilly offer direct-to-telehealth programs bundling FDA-approved drugs with adherence kits and reimbursement interfaces [2].
If you are seeking weight-loss treatment, the safest and most reliable options are currently:
- Wegovy (Novo Nordisk) – FDA-approved for chronic weight management [3]
- Zepbound (Eli Lilly) – FDA-approved for weight loss [3]
- Saxenda (Novo Nordisk) – FDA-approved, often used with generics [3]
For access, consult licensed telehealth platforms that now focus on approved medications, such as Ro and Hims & Hers [3]. Compounded GLP-1s remain legally permissible only in rare cases (e.g., specific allergies or unavailable dosages), but mainstream telehealth platforms have largely eliminated them [3][12].